Lithium pyrroloquinoline quinone

N/A

Report date: 2025/04/30 16:00:37
NME

Base Information

Drug NameLithium pyrroloquinoline quinone
Drug Alias Name吡咯喹啉醌锂
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 inhibitors
TargetsGlycogen synthase kinase-3
Therapy Area/IndicationsObesity, MaternalGlaucomaAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPending
Originator CompaniesShanghai Rixin Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSapienza University Of RomeFederico Ii University
Inactive CompaniesShanghai Rixin Pharmaceutical Technology Co LtdThe University Of Oklahoma
Active IndicationsGlaucoma
Inactive IndicationsObesity, MaternalAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A